Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 5/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MELK | Q14680 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14947692 | 0.87 | GRM4 (0.43) | GRM4CFTRDYRK1BMTORNOTUM | |
| SCHEMBL14947693 | 0.87 | GRM4 (0.43) | GRM4CFTRDYRK1BMTORNOTUM | |
| SCHEMBL20282465 | 0.84 | CFTR (0.44) | GRM4CFTRDYRK1BMTORNOTUM | |
| SCHEMBL18254780 | 0.81 | RXRA (0.40) | ESRRAADORA3POLB | |
| SCHEMBL2609426 | 0.81 | CFTR (0.43) | CFTR | |
| SCHEMBL30036869 | 0.80 | CFTR (0.43) | GRM4CFTRDYRK1BMTORNOTUM | |
| SCHEMBL20162857 | 0.80 | CFTR (0.43) | GRM4CFTRDYRK1BMTORNOTUM | |
| SCHEMBL20163069 | 0.80 | CFTR (0.43) | GRM4CFTRDYRK1BMTORNOTUM | |
| SCHEMBL30038218 | 0.80 | CFTR (0.43) | GRM4CFTRDYRK1BMTORNOTUM | |
| SCHEMBL17066201 | 0.80 | ALDH1A1 (0.41) | MTORNOTUMDRD4DRD3ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-10745398-B2 | 2-(het)aryl-substituted fused heterocycle derivatives as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-08-18 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190330219-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | PFIZER INC. | 2019-10-31 | — | — | US | disclosed |
| US-10377762-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | BCL6, BCL6B, EZH2 | GRM4 1784/4885CFTR 2672/4885DYRK1B 1343/4885 |
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | GRM4 1140/4885CFTR 1345/4885DYRK1B 4373/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | GRM4 3701/4885CFTR 2932/4885DYRK1B 706/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | GRM4 3701/4885CFTR 2932/4885DYRK1B 706/4885 |
| US-10377762-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RY2 | GRM4 2431/4885CFTR 1/4885DYRK1B 1247/4885 |
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RX3 | GRM4 2637/4885CFTR 1/4885DYRK1B 1191/4885 |
| US-10745398-B2 | 2-(het)aryl-substituted fused heterocycle derivatives as pesticides | CYP4X1, CYP1A1, CYP8B1 | GRM4 2064/4885CFTR 2217/4885DYRK1B 4118/4885 |
| US-20190330219-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, SLC26A3, P2RY2 | GRM4 2431/4885CFTR 1/4885DYRK1B 1247/4885 |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | GRM4 2223/4885CFTR 1/4885DYRK1B 1487/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | GRM4 1629/4885CFTR 4224/4885DYRK1B 566/4885 |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | GRM4 2805/4885CFTR 1694/4885DYRK1B 4269/4885 |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RY2 | GRM4 2431/4885CFTR 1/4885DYRK1B 1247/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | GRM4 3389/4885CFTR 3987/4885DYRK1B 3266/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | GRM4 3701/4885CFTR 2932/4885DYRK1B 706/4885 |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BAZ2A | GRM4 1140/4885CFTR 1345/4885DYRK1B 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.